- Home
- KROS vs CRMD Comparison
KROS vs CRMD Comparison
Compare KROS & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | CRMD |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 605.9M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | KROS | CRMD |
|---|---|---|
| Price | $14.18 | $7.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $23.00 | $15.29 |
| AVG Volume (30 Days) | 263.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.85 | ★ 67.03 |
| EPS | ★ 2.68 | 1.97 |
| Revenue | N/A | ★ $43,472,170.00 |
| Revenue This Year | $6,898.87 | $627.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.62 | ★ $3.75 |
| Revenue Growth | N/A | ★ 66363.08 |
| 52 Week Low | $9.12 | $5.60 |
| 52 Week High | $22.55 | $17.43 |
Technical Indicators
Market Signals| Indicator | KROS | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 20.59 | 39.68 |
| Support Level | $13.42 | $6.55 |
| Resistance Level | $15.02 | $8.53 |
| Average True Range (ATR) | 0.59 | 0.26 |
| MACD | -0.20 | 0.08 |
| Stochastic Oscillator | 0.69 | 24.74 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.